The Recall Desk
Agency classClass IIOur severity:SevereFDA (Drugs)·D-1687-2019·Announced 2019-08-14

RXQ Compounding Recalls Moxifloxacin Ophthalmic Solution Due to Sterility Concerns

RXQ Compounding LLC is recalling Moxifloxacin 0.5% Ophthalmic Solution syringes because the product lacks assurance of sterility.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The agency classified this as FDA Class II. Per the rubric, FDA Class II recalls with potential for adverse health consequences (such as sterility failure in ophthalmic products) are mapped to a score of 4 (Severe), as they represent a significant risk of harm even if not explicitly Class I.

Plain-English summary

RXQ Compounding LLC is voluntarily recalling Moxifloxacin 0.5% Ophthalmic Solution syringes, 1 mL per syringe (NDC: 70731-0973-81). The recall was initiated because the product lacks assurance of sterility. The affected product was distributed nationwide in the United States.

The recall includes all lots within their expiration dates. The U.S. Food and Drug Administration has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider for further instructions. Patients should not discard the product until directed by a healthcare professional or the recalling firm.

The recalled product

Product
MOXIFLOXACIN 0.5% OPHTH SOLUTION SYRINGE, 1 ML per syringe, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0973-81
Manufacturer
RXQ Compounding LLC
Category
Drug — Ophthalmic Solution
Hazard

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • All lots within expiry

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 86 recalled by RXQ Compounding LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 86 products in this recall →

Related recalls

Same manufacturer · RXQ Compounding LLC

See all →

Same hazard · sterility failure

See all →

Similar recalls